Journal of Peking University (Health Sciences) ›› 2020, Vol. 52 ›› Issue (4): 614-620. doi: 10.19723/j.issn.1671-167X.2020.04.003

Previous Articles     Next Articles

Clinical profile of pheochromocytoma and paraganglioma with normal plasma free metanephrines

Lu LIU1,Jie TIAN2,Kai WU1,Ying GAO1,(),Zheng ZHANG2,(),Jun-qing ZHANG1,Xiao-hui GUO1   

  1. 1. Department of Endocrinology, Peking University First Hospital, Beijing 100034, China
    2. Department of Urology, Peking University First Hospital, Beijing 100034, China
  • Received:2020-03-16 Online:2020-08-18 Published:2020-08-06
  • Contact: Ying GAO,Zheng ZHANG E-mail:bjgaoying@yahoo.com;doczhz@aliyun.com
  • Supported by:
    PUHSC Clinical Research Project(PUCRP201302);Interdisciplinary Medicine Seed Fund of Peking University(BMU2018MX026);the Scientific Research Seed Fund of Peking University First Hospital(2018SF066)

RICH HTML

  

Abstract:

Objective: Plasma free metanephrines (MNs) have been widely used as an initial test for pheochromocytoma and paraganglioma (PPGL). PPGL without MNs elevation has been reported on rare occasions. The objective of this study was to analyze the clinical profile of sporadic PPGL patients with normal MNs. Methods: In the study, 104 patients with sporadic PPGL diagnosed by histopathology in Peking University First Hospital from March 2015 to January 2020 were enrolled. All the patients had plasma MNs result, of whom, eight (7.69%) were with normal MNs. The reasons for their medical visits, clinical manifestations, the levels of plasma free MNs, 3-methoxytyramine (3-MT), catecholamines and chromogranin A (CgA), and the imaging findings were documented. Their preoperative diagnosis, perioperative medical management, and intraoperative blood pressure were analyzed. All the data mentioned above were compared with the MNs elevated group. The postoperative follow-up for MNs normal patients were applied. Results: For the eight PPGL patients with normal plasma MNs, the most common clinical symptoms were sweating (3/8), abdominal and back pain (3/8), headache (2/8), palpitations (2/8), and fatigue (2/8). There were no significant differences in plasma free 3-MT and catecholamines’ diagnostic positive rate between the MNs normal group and MNs elevated group, but the rate for plasma CgA was significantly decreased in the MNs normal group (2/5 vs. 41/43, P=0.005). No significant difference was found for the incidence of typical findings by enhanced CT between the two groups. In these eight MNs normal patients, six were diagnosed with PPGL by the previous history of PPGL, typical symptoms and CT findings, or elevation of 3-MT, CgA levels or positive results of PET-CT; two patients were misdiagnosed as nonfunctioning adenoma or primary aldosteronism. All these MNs normal patients underwent preoperative management with alpha adrenergic receptor blockers, of whom, one had an average intraoperative arterial pressure <60 mmHg during surgery. The median follow-up time for the eight patients was 1.5 (0.5-4.5) years. No evidence of new tumors was found on the enhanced CT scans. Two MNs normal patients’ plasma 3-MT and (or) CgA decreased to normal. Conclusion: For patients with adrenal or retroperitoneal tumors, typical symptoms or a previous history of PPGL, normal plasma MNs is not a sufficient exclusion for PPGL. Plasma 3-MT, catecholamine, CgA results and the imaging findings are helpful for the diagnosis of PPGL. We recommend patients with suspected MNs normal PPGL take alpha adrenergic receptor blockers as preoperative blockade, but should avoid overdose. Postoperative follow-up for patients with normal MNs should focus on the positive biochemical markers before surgery.

Key words: Pheochromocytoma, Paraganglioma, Metanephrines, Diagnosis

CLC Number: 

  • R736

Table 1

Clinical features in PPGL patients with normal plasma free MNs"

Table 2

Perioperative management and follow-up data about PPGL patients with normal plasma free MNs"

Table 3

Comparison of clinical data between MNs normal and MNs elevated groups in PPGL patients"

Items All patients MNs normal MNs elevated P value
Total, n 104 8 96
Male/female 49/55 2/6 47/49 0.349
Age/years 46(11-76) 55(23-70) 46(11-76) 0.494
Initial/recurrence, n/N 100/4 6/2 94/2 0.029
PCC/PGL, n/N 80/24 6/2 74/22 1.000
Metastasis, n 4 1 3 0.278
Symptoms, n/N
Headache 42/104 2/8 40/96 0.584
Palpitations 42/104 2/8 40/96 0.584
Sweating 37/104 3/8 34/96 1.000
Dizziness 18/104 1/8 17/96 1.000
Abdominal/back pain 17/104 3/8 14/96 0.235
Pallor 10/104 0/8 10/96 1.000
Nausea/vomiting 11/104 1/8 10/96 1.000
Fatigue 7/104 2/8 5/96 0.090
Hypertension 80/104 7/8 73/96 0.762
Classic triad, n/N
3 presented 14/104 1/8 13/96 1.000
1-2 presented 54/104 3/8 51/96 0.630
None presented 36/104 4/8 32/96 0.572
BMI/(kg/m2) 22.65(15.77-32.53) 25.56(17.67-27.85) 22.42(15.77-32.53) 0.118
Tumor diameter/cm 5.00(1.20-14.00) 4.75(1.20-6.00) 5.00(1.50-14.00) 0.081

Table 4

Comparison of biochemical testing and imaging finding data between MNs normal and MNs elevated groups in PPGL patients"

MNs normal MNs elevated P value
MN/(nmol/L) 0.11(<0.08-0.22) 0.71(<0.08->20.56)
MN, n/N 0/8 45/96 0.028
NMN/(nmol/L) 0.395(0.20-0.71) 4.87(0.42->20.56)
NMN, n/N 0/8 94/96 0.000
3-MT/(nmol/L) <0.08(<0.08-2.27) 0.12(<0.08-0.46)
3-MT, n/N 2/7 6/93 0.096
E/(pmol/L) 0.049(0.027-0.169) 0.087(0.027-89.138)
E, n/N 0/3 6/40 1.000
NE/(pmol/L) 8.523(0.467-22.367) 9.836(0.284-147.23)
NE, n/N 2/3 31/40 0.558
DA/(pmol/L) 0.052(0.039-0.157) 0.056(0.033-1.18)
DA, n/N 0/3 2/40 1.000
CgA/(μg/L) 60.02(34.37-1295.36) 369.37(36.85-1669.96)
CgA, n/N 2/5 41/43 0.005
Classic findings of CT, n/N 5/8 85/96 0.125
[1] Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best[J]. JAMA, 2002,287(11):1427-1434.
doi: 10.1001/jama.287.11.1427 pmid: 11903030
[2] Unger N, Pitt C, Schmidt IL, et al. Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass[J]. Eur J Endocrinol, 2006,154(3):409-417.
pmid: 16498054
[3] Hickman PE, Leong M, Chang J, et al. Plasma free metanephrines are superior to urine and plasma catecholamines and urine catecholamine metabolites for the investigation of phaeochromocytoma[J]. Pathology, 2009,41(2):173-177.
[4] Grouzmann E, Drouard-Troalen L, Baudin E, et al. Diagnostic accuracy of free and total metanephrines in plasma and fractionated metanephrines in urine of patients with pheochromocytoma[J]. Eur J Endocrinol, 2010,162(5):951-960.
pmid: 20142367
[5] Unger N, Hinrichs J, Deutschbein T, et al. Plasma and urinary metanephrines determined by an enzyme immunoassay, but not serum chromogranin A for the diagnosis of pheochromocytoma in patients with adrenal mass[J]. Exp Clin Endocrinol Diabetes, 2012,120(8):494-500.
doi: 10.1055/s-0032-1309007 pmid: 22696168
[6] Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2014,99(6):1915-1942.
[7] 中华医学会内分泌学分会肾上腺学组. 嗜铬细胞瘤和副神经节瘤诊断治疗的专家共识[J]. 中华内分泌代谢杂志, 2016,32(3):181-187.
[8] Plouin PF, Amar L, Dekkers OM, et al. European society of endocrinology clinical practice guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma[J]. Eur J Endocrinol, 2016,174(5):G1-G10.
[9] Bozin M, Lamb A, Putra LJ. Pheochromocytoma with negative metanephrines: a rarity and the significance of dopamine secreting tumors[J]. Urol Case Rep, 2017,12:51-53.
pmid: 28337414
[10] 曹万里, 黄宝星, 成康, 等. 血浆游离甲氧肾上腺素和甲氧基去甲肾上腺素正常的嗜铬细胞瘤/副神经节瘤患者的临床特点[J]. 中华临床医师杂志: 电子版, 2015,9(2):200-205.
[11] 刘颖姝, 李乐乐, 窦京涛, 等. 偶发嗜铬细胞瘤患者术中血流动力学变化的相关因素[J]. 中华医学杂志, 2018,98(36):2905-2909.
[12] Poudyal S, Pradhan M, Chapagain S, et al. Marker-negative pheochromocytoma associated with inferior vena cava thrombosis[J/OL]. Case Rep Urol, 2017, 2017: 6270436(2017-06-15)[2020-03-01]. https://www.hindawi.com/journals/criu/2017/6270436/.
[13] Lopez-Gomez J, Salazar-Alvarez MA, Adame RY, et al. Metasta-tic pheochromocytoma to liver without elevation of metanephrines and catecholamines[J]. Int J Surg Case Rep, 2016,29:71-75.
pmid: 27821293
[14] Kota SK, Kota SK, Panda S, et al. Pheochromocytoma: an uncommon presentation of an asymptomatic and biochemically silent adrenal incidentaloma[J]. Malays J Med Sci, 2012,19(2):86-91.
[15] Heavner MG, Krane LS, Winters SM, et al. Pheochromocytoma diagnosed pathologically with previous negative serum markers[J]. J Surg Oncol, 2015,112(5):492-495.
pmid: 26384104
[16] Eisenhofer G, Lenders JW, Goldstein DS, et al. Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines[J]. Clin Chem, 2005,51(4):735-744.
pmid: 15718487
[17] Pillai D, Ross HA, Kratzsch J, et al. Proficiency test of plasma free and total metanephrines: report from a study group[J]. Clin Chem Lab Med, 2009,47(6):786-790.
pmid: 19445649
[18] Pillai D, Callen S. Pilot quality assurance programme for plasma metanephrines[J]. Ann Clin Biochem, 2010,47(Pt 2):137-142.
[1] Xinxin CHEN, Zhe TANG, Yanchun QIAO, Wensheng RONG. Caries experience and its correlation with caries activity of 4-year-old children in Miyun District of Beijing [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 833-838.
[2] Hua ZHONG, Yuan LI, Liling XU, Mingxin BAI, Yin SU. Application of 18F-FDG PET/CT in rheumatic diseases [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 853-859.
[3] Zhengfang LI,Cainan LUO,Lijun WU,Xue WU,Xinyan MENG,Xiaomei CHEN,Yamei SHI,Yan ZHONG. Application value of anti-carbamylated protein antibody in the diagnosis of rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 729-734.
[4] Hai-hong YAO,Fan YANG,Su-mei TANG,Xia ZHANG,Jing HE,Yuan JIA. Clinical characteristics and diagnostic indicators of macrophage activation syndrome in patients with systemic lupus erythematosus and adult-onset Still's disease [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 966-974.
[5] Yan XIONG,Xin LI,Li LIANG,Dong LI,Li-min YAN,Xue-ying LI,Ji-ting DI,Ting LI. Evaluation of accuracy of pathological diagnosis based on thyroid core needle biopsy [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 234-242.
[6] Xue-mei HA,Yong-zheng YAO,Li-hua SUN,Chun-yang XIN,Yan XIONG. Solid placental transmogrification of the lung: A case report and literature review [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 357-361.
[7] Bo-han NING,Qing-xia ZHANG,Hui YANG,Ying DONG. Endometrioid adenocarcinoma with proliferated stromal cells, hyalinization and cord-like formations: A case report [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 366-369.
[8] Rui-jie CAO,Zhong-qiang YAO,Peng-qing JIAO,Li-gang CUI. Comparison of diagnostic efficacy of different classification criteria for Takayasu arteritis in Chinese patients [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1128-1133.
[9] Zhe HAO,Shu-hua YUE,Li-qun ZHOU. Application of Raman-based technologies in the detection of urological tumors [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 779-784.
[10] Bo YU,Yang-yu ZHAO,Zhe ZHANG,Yong-qing WANG. Infective endocarditis in pregnancy: A case report [J]. Journal of Peking University (Health Sciences), 2022, 54(3): 578-580.
[11] MENG Guang-yan,ZHANG Yun-xiao,ZHANG Yu-xin,LIU Yan-ying. Clinical characteristics of central nervous system involvement in IgG4 related diseases [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1043-1048.
[12] ZHAI Li,QIU Nan,SONG Hui. Multicentric reticulohistiocytosis: A case report [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1183-1187.
[13] LIU Lei,QIN Yan-chun,WANG Guo-liang,ZHANG Shu-dong,HOU Xiao-fei,MA Lu-lin. Strategy of reoperation for pheochromocytoma and paraganglioma [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 793-797.
[14] YUAN Yuan,LANG Ning,YUAN Hui-shu. CT spectral curve in differentiating spinal tumor metastasis and infections [J]. Journal of Peking University (Health Sciences), 2021, 53(1): 183-187.
[15] Qi KANG,Ji-xin ZHANG,Ying GAO,Jun-qing ZHANG,Xiao-hui GUO. Analysis of diagnosis and treatment of 100 patients with Hürthle cell adenoma [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1098-1101.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!